XML 80 R55.htm IDEA: XBRL DOCUMENT
v3.25.0.1

SUMMARIZED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Quarterly Financial Information Disclosure [Abstract] |
Schedule of Quarterly Financial Results |
Years Ended December 31, | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
| (in millions, except per share data)
2024 |  |  |  |  |  |  |  |  |
Net sales | $ | 1,329.9 |  |  | $ | 1,369.4 |  |  | $ | 1,354.4 |  |  | $ | 1,385.8 |  |  | $ | 5,439.5 |
Gross profit | 1,043.0 |  |  | 1,093.9 |  |  | 1,091.5 |  |  | 1,093.6 |  |  | 4,322.0 |
Income from continuing operations, net of tax | 324.9 |  |  | 364.0 |  |  | 362.1 |  |  | 345.0 |  |  | 1,396.0 |
Income from discontinued operations, net of tax (a) | 26.1 |  |  | 1.0 |  |  | 2,707.3 |  |  | 39.3 |  |  | 2,773.7 |
Net income (a) | 351.0 |  |  | 365.0 |  |  | 3,069.4 |  |  | 384.3 |  |  | 4,169.7 |
Net income attributable to Edwards Lifesciences Corporation (a) | 351.9 |  |  | 366.3 |  |  | 3,070.8 |  |  | 385.6 |  |  | 4,174.6 |
Basic earnings per share: |  |  |  |  |  |  |  |  |
Continuing operations | 0.54 |  |  | 0.61 |  |  | 0.61 |  |  | 0.58 |  |  | 2.34 |
Discontinued operations | 0.04 |  |  | — |  |  | 4.53 |  |  | 0.07 |  |  | 4.64 |
Basic earnings per share | 0.58 |  |  | 0.61 |  |  | 5.14 |  |  | 0.65 |  |  | 6.98 |
Diluted earnings per share: |  |  |  |  |  |  |  |  |
Continuing operations | 0.54 |  |  | 0.61 |  |  | 0.61 |  |  | 0.58 |  |  | 2.34 |
Discontinued operations | 0.04 |  |  | — |  |  | 4.52 |  |  | 0.07 |  |  | 4.63 |
Diluted earnings per share | 0.58 |  |  | 0.61 |  |  | 5.13 |  |  | 0.65 |  |  | 6.97 |
2023 |  |  |  |  |  |  |  |  |
Net sales | $ | 1,221.3 |  |  | $ | 1,278.9 |  |  | $ | 1,243.4 |  |  | $ | 1,266.4 |  |  | $ | 5,010.0 |
Gross profit | 992.3 |  |  | 1,031.1 |  |  | 992.8 |  |  | 1,015.4 |  |  | 4,031.6 |
Income from continuing operations | 300.6 |  |  | 251.4 |  |  | 334.9 |  |  | 333.1 |  |  | 1,220.0 |
Income from discontinued operations, net of tax | 39.9 |  |  | 54.1 |  |  | 48.8 |  |  | 36.6 |  |  | 179.4 |
Net income | 340.5 |  |  | 305.5 |  |  | 383.7 |  |  | 369.7 |  |  | 1,399.4 |
Net income attributable to Edwards Lifesciences Corporation | 340.5 |  |  | 307.1 |  |  | 384.9 |  |  | 369.9 |  |  | 1,402.4 |
Basic earnings per share: |  |  |  |  |  |  |  |  |
Continuing operations | 0.49 |  |  | 0.42 |  |  | 0.55 |  |  | 0.55 |  |  | 2.02 |
Discontinued operations | 0.07 |  |  | 0.09 |  |  | 0.08 |  |  | 0.06 |  |  | 0.29 |
Basic earnings per share | 0.56 |  |  | 0.51 |  |  | 0.63 |  |  | 0.61 |  |  | 2.31 |
Diluted earnings per share: |  |  |  |  |  |  |  |  |
Continuing operations | 0.49 |  |  | 0.41 |  |  | 0.55 |  |  | 0.55 |  |  | 2.01 |
Discontinued operations | 0.07 |  |  | 0.09 |  |  | 0.08 |  |  | 0.06 |  |  | 0.29 |
Diluted earnings per share | 0.56 |  |  | 0.50 |  |  | 0.63 |  |  | 0.61 |  |  | 2.30 |
_______________________________________________________________________________ (a) The third quarter of 2024 includes a $3.3 billion gain from the sale of Critical Care. See Note 5 for additional information.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration